Cardiovascular claims require rigorous validation. Not optimism.
GLP-1/SGLT2 literature explosion
Cardiovascular benefit claims proliferating faster than review capacity. Which findings replicate? Which are overfitted to specific populations?
Endpoint complexity
MACE, heart failure hospitalization, renal outcomes — composite endpoints need verified support across trials, not cherry-picked results.
Regulatory pressure
Cardiovascular outcome trials are expensive. Evidence synthesis before Phase 3 commitment saves millions in failed development.
Adversarial review before publication or trial commitment.
Multi-model adversarial review
Claude and Gemini attack your claims from different architectural perspectives, producing a claim-support audit and independent contradiction memo. No single model's blind spots.
57% rejection rate
Claims that survive multi-model adversarial attack are stronger submissions. Claims that don't survive save you a rejection cycle.
Citation verification
Every DOI checked against live databases. 53% of AI-generated citations contain errors.
What the pipeline produces.
Pre-publication adversarial review: Peer reviewers at top cardiology journals scrutinize methodology and evidence quality. The question is whether you see the weaknesses first. Multi-model attack surfaces what a single reviewer might miss.
Research audit for cardiovascular work.
Send one hypothesis, evidence synthesis question, or draft section. We run it through cross-architecture adversarial review.